Drybench Patent.
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM, NDA 050684
The patents and exclusivities FDA's Orange Book lists for NDA 050684 as captured on 14 October 2026, each date named by its rule and its rows, and the rows of FDA's Paragraph IV list that give this NDA's number, as captured on 17 October 2026. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
The Orange Book capture of 14 October 2026 lists no patent and no exclusivity for NDA 050684.
Products
Each product number FDA lists under NDA 050684, as listed. The sections below name products by these numbers.
Product 001 · ZOSYN
- Dosage form; route
- INJECTABLE;INJECTION
- Strength
- EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- Approval date as listed
- 22 Oct 1993
- Type as listed
- DISCN
- Applicant as listed
- WYETH PHARMACEUTICALS LLC
Product 002 · ZOSYN
- Dosage form; route
- INJECTABLE;INJECTION
- Strength
- EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- Approval date as listed
- 22 Oct 1993
- Type as listed
- DISCN
- Applicant as listed
- WYETH PHARMACEUTICALS LLC
Product 003 · ZOSYN
- Dosage form; route
- INJECTABLE;INJECTION
- Strength
- EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- Approval date as listed
- 22 Oct 1993
- Type as listed
- DISCN
- Applicant as listed
- WYETH PHARMACEUTICALS LLC
Product 004 · ZOSYN
- Dosage form; route
- INJECTABLE;INJECTION
- Strength
- EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
- Approval date as listed
- 22 Oct 1993
- Type as listed
- DISCN
- Applicant as listed
- WYETH PHARMACEUTICALS LLC
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
The Orange Book capture of 14 October 2026 lists no patent for NDA 050684.
Listed exclusivities
Each exclusivity FDA lists for NDA 050684, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
The Orange Book capture of 14 October 2026 lists no exclusivity for NDA 050684.
Paragraph IV list rows giving NDA 050684
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 050684, each cell as listed.
FDA's Paragraph IV list names no patent number, so it does not say which of the patents on this page an applicant certified against.
The list gives the last qualifying patent's expiry without pediatric exclusivity; in the app's Patents view, the Orange Book lists any *PED period as a separate row with its own date. The two dates describe different things. A blank cell is one FDA left blank in its list. Dates are FDA's own; the last qualifying patent expiry is not recomputed from the Orange Book.
Rows whose RLD/NDA cell we could not read as exactly one NDA number are kept apart on the list page; some may concern this product.
Rows on FDA's Paragraph IV list whose RLD/NDA cell gives NDA 050684
Piperacillin Sodium and Tazobactam Sodium · For Injection · 12 g/1.5 g per vial (pharmacy bulk)
RLD/NDA as listed: Zosyn 50684- First PIV submission
- 6 Dec 2011
- ANDAs
- 1
- 180-day status
- Eligible
- Decision posted
- 22 Feb 2022
- First applicant approval
- 29 Oct 2014
- First marketing
- 24 Jan 2017
- Last qualifying patent expiry (as listed by FDA)
- 14 Apr 2023
Piperacillin Sodium and Tazobactam Sodium · For Injection · 2.25 g/vial 3.375 g/vial 4.5 g/vial
RLD/NDA as listed: Zosyn 50684- First PIV submission
- PIV received prior to 2/5/2009
- ANDAs
- blank
- 180-day status
- blank
- Decision posted
- blank
- First applicant approval
- blank
- First marketing
- blank
- Last qualifying patent expiry (as listed by FDA)
- blank
Piperacillin Sodium and Tazobactam Sodium · For Injection · 36 mg/4.5 g per vial (pharmacy bulk)
RLD/NDA as listed: Zosyn 50684- First PIV submission
- PIV received prior to 2/5/2009
- ANDAs
- 1
- 180-day status
- Eligible
- Decision posted
- 1 Dec 2020
- First applicant approval
- 15 Sep 2009
- First marketing
- 29 Oct 2009
- Last qualifying patent expiry (as listed by FDA)
- 14 Apr 2023
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week